Moderna's flu vaccine shows positive study results, paving path for combo shot
The Moderna Inc. headquarters in Cambridge, Massachusetts, on March 26, 2024.
Adam Glanzman | Bloomberg | Getty pictures
Modern On Monday, the experimental MRNA-based flu vaccine gave a stronger immune response on Monday than currently available in a study in a late stage that cleared a way for the product and the separate combination of flu and covid from the company.
Moderna voluntarily withdrew an application in May, which requested the approval of his combination shot on Covid-19 and influenza, and said that it has plans to apply for them again with efficiency data from the phase three-day study on its independent flu vaccine. This decision came after discussions with the Food and Drug Administration, which deals with a massive overhaul in the context of the health and human service -secretary Robert F. Kennedy Jr., a prominent vaccine skeptic.
With the new data, the company plans to arrange the application for combination vaccine and the submission of its independent flu vaccination later this year, Stephen Hoge, head of the company's research and development head, said in an interview.
If the supervisory authorities agree to the flu vaccine, the company can advance the combination shot, said Hoge. He added that Moderna was expecting permits for both recordings next year.
The Moderna shares rose by almost 3%in the Premarket trade on Monday.
Hoge said that the combination Jab simplifies vaccination what “the health system” will help by reducing the workload of doctors and nurses, reducing costs and improving admission to patients.
So far, the company seems to be the leader of the race against the race Pfizer And Novavax bring a combination onto the market. While Moderna has no specific intake projections for its individual products, covid, flu and breathing syncytial virus are several dollar markets.
“We obviously hope that our products will enable us to earn our appropriate share of them,” he said.
More CNBC health insurance
In the three-study phase, more than 40,000 adults from 50 years of age followed, who happened to receive a single dose of Moderna's shot, MRNA-1010 or a standard competition vaccine. Modernas shot was 26.6% more effective than the other vaccine in the overall study population.
The MRNA 1010-JAB also showed a strong effectiveness for each of the most important influenza tribes in the shot, including A/H1N1, A/H3N2 and the B/Victoria lines. Moderna said that the benefits of the vaccine in different age groups, people with various risk factors and earlier vaccination status were consistent against the flu.
In adults from the age of 65, the shot was 27.4% more effective than the standard flu vaccine.
The effectiveness results are “an important milestone for our efforts to reduce the burden of influenza in older adults,” said Stephane Bancel, CEO of Moderna, in a press release. “The severity of the past flu season underlines the need for more effective vaccines.”
Moderna cited data from the centers for the control and prevention of diseases and shows that seasonal hospital stays and outpatient visits reached a 15-year high during the 2024 to 2025 season. According to the CDC, more than 600,000 Americans were hospitalized last year due to a flu -related illness.
The safety data of the MRNA-1010-vaccine matched three studies on the shot with earlier results from another phase.
Moderna's shares went back by more than 30% in Monday and were largely fueled by a series of steps from the Trump administration in order to change vaccine policy and undermine the immunizations. The administration in May announced a contract that was awarded Moderna for the development of her bird flu vaccine for humans.
When asked about the uncertain regulatory environment in the USA, Moge said that Moderna was closely with the FDA to understand what your requirements are and how you can satisfy you.
“I think we have a fairly clear way in connection with flu,” he said.
